ASIA unversity:Item 310904400/111350
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 94286/110023 (86%)
Visitors : 21693411      Online Users : 702
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/111350


    Title: A controlled trial of Sheng-Yu-Tang for post-hematopoietic stem cell transplantation leukemia patients: A proposed protocol and insights from a preliminary pilot study
    Authors: 馮堂正;Fleischer, Tom;張東迪;Chang, Tung-Ti;蔣仁槐;Chiang, Jen-Huai;顏宏融;Yen, Hung-Rong;*
    Contributors: 生物科技學系
    Date: 2018-01
    Issue Date: 2018-08-20 01:44:24 (UTC+0)
    Abstract: Introduction: Hematopoietic stem cell transplantation has become a well-established treatment for hematologic disorders including acute leukemia. However, long-term survival rates following this procedure are still extremely low, due to posttransplantation relapse, infections, and graft-versus-host disease. We propose that adjunctive Chinese herbal medicine may benefit posttransplantation patients. In preparation for a randomized clinical trial, we conducted a pilot trial. Methods and Analysis: Between September 2015 and June 2017, 18 patients were consecutively enrolled at China Medical University Hospital and followed for up to 1 year. Fresh blood samples were obtained on a monthly basis, and immune reconstitution was analyzed. In addition to the standard-care treatment administered by their oncologist, a number of patients also received a Chinese herbal formula (Sheng-Yu-Tang) for up to 6 months. Results were used to improve on study protocol and estimate required sample size for a future randomized trial. Ethics and Dissemination: Study protocol was approved by the institutional review board of China Medical University Hospital (DMR-105-005), and all participants provided informed consent.

    Keywords HSCT, acute leukemia, immune reconstitution, Chinese herbal medicine
    Relation: INTEGRATIVE CANCER THERAPIES
    Appears in Collections:[Department of Biotechnology] Journal Article

    Files in This Item:

    File SizeFormat
    index.html0KbHTML431View/Open


    All items in ASIAIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback